Published Date: 13 Mar 2023
Electrophysiologist John Mandrola, MD. and Rachel Lampert, MD, reviewed the LIVE-HCM study comparing exercise and no exercise in people with hypertrophic cardiomyopathy.
Read Full NewsWechsler discusses why less frequent dosing matters to patients with severe asthma, plus VALIANT's safety profile and what's next for the field.
Tozorakimab Cuts COPD Mucus Plugging, With George Washko, MD
Chronic Proton Pump Inhibitor Use Linked to More Asthma Exacerbations
Adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive now have a second self-administration option for the complement inhibitor zilucoplan.
Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.
Recognizing Familial Chylomicronemia Syndrome in the APOC3 Era
1.
A prostate cancer risk prediction algorithm could help target men at highest risk
2.
Guideline on management of early-stage non-small cell lung cancer released
3.
Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.
4.
Adding cell-based vaccine to liver cancer therapy can slow cancer progression
5.
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.
1.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
2.
Navigating the Complexities of Melanoma Staging: A Comprehensive Guide
3.
The Pivotal Role of Telomerase in Breast Cancer Therapy Resistance and Treatment Strategies
4.
Mast Cell-Tumor Cell Interactions in OSCC: Genetic and microRNA Insights
5.
The Silent Signs: Uncovering Stomach Cancer Symptoms Before It's Too Late
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation